文献速递肾移植

快速生物层干涉法检测尿CXCL9无创诊断肾移植后细胞浸润

Rapid Biolayer Interferometry Measurements of Urinary CXCL9 to Detect Cellular Infiltrates Noninvasively After Kidney Transplantation.
PubMed 文献 · Kidney Int Rep · 2017-06-21

本研究开发了基于生物层干涉法(BLI)的快速尿液CXCL9检测(<1小时),在86份尿样中与标准ELISA验证一致,并在56例肾移植受者中分析。BLI检测显示急性细胞排斥(ACR)患者尿CXCL9>200 pg/ml,而无细胞浸润的稳定患者≤100 pg/ml。治疗后的系列检测可发现活检证实的移植物内浸润,提示该技术有潜力作为即时无创生物标志物指导ACR诊疗。

要点

  • BLI法可在<1小时内快速、准确、可重复地检测尿液CXCL9。
  • 尿CXCL9>200 pg/ml提示ACR,≤100 pg/ml见于无细胞浸润的稳定患者。
  • 治疗后的BLI检测仍可发现活检证实的移植物内浸润。

核心结论

  • 基于BLI的尿液CXCL9快速检测有望作为即时无创生物标志物用于肾移植后ACR的诊断和治疗指导。

研究设计与样本

  • 开发基于BLI的尿液CXCL9快速检测(<1小时),在86份肾移植受者尿样中与标准ELISA进行验证。
  • 随后用BLI分析56例肾移植受者样本,包括46例血清肌酐急性升高者(活检证实的ACR 22例、亚临床排斥15例、无浸润9例)和10例稳定受者的监测活检。
  • 对6例ACR治疗后受者系列检测血清肌酐和尿CXCL9,并与随访活检组织学诊断关联。

主要发现

  • BLI在<1小时内准确、可重复地检测尿CXCL9。
  • BLI结果显示ACR患者尿CXCL9>200 pg/ml,而肾功能稳定且无细胞浸润者≤100 pg/ml。
  • ACR治疗后样本中,BLI检测到的CXCL9可发现活检证实的移植物内浸润,尽管治疗使血清肌酐下降。

关键数值与推荐

  • 尿CXCL9>200 pg/ml见于ACR患者,≤100 pg/ml见于无细胞浸润的稳定患者。

临床怎么用

  • BLI法检测尿CXCL9可在1小时内完成,便于临床快速决策。
  • 尿CXCL9>200 pg/ml提示ACR可能,≤100 pg/ml提示无细胞浸润。
  • ACR治疗后系列监测尿CXCL9有助于发现残留的移植物内浸润。

局限性

  • 本研究为原理验证性研究,样本量有限,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Measuring the chemokine CXCL9 in urine by enzyme-linked immunosorbent assay (ELISA) can diagnose acute cellular rejection (ACR) noninvasively after kidney transplantation, but the required 12- to 24-hour turnaround time is not ideal for rapid, clinical decision-making. METHODS: We developed a biolayer interferometry (BLI)-based assay to rapidly measure urinary CXCL9 in <1 hour. We validated this new assay versus standard ELISA in 86 urine samples from kidney transplantation recipients with various diagnoses. We then used BLI to analyze samples from 56 kidney transplantation recipients, including 46 subjects who experienced an acute rise in serum creatinine associated with biopsy-proven ACR (n = 22), subclinical rejection (n = 15), or no infiltrates (n = 9), and 10 stable kidney transplantation recipients with surveillance biopsies. To assess its usefulness in detecting adequacy of therapy we serially measured serum creatinine and urinary CXCL9 in 6 subjects after treatment for ACR, and correlated the results with histological diagnoses on follow-up biopsies. RESULTS: BLI accurately and reproducibly detected urinary CXCL9 in <1 hour. BLI-based results showed that urinary CXCL9 was >200 pg/ml in subjects with ACR and ≤100 pg/ml in subjects with stable kidney function without cellular infiltrates. In samples obtained after treatment for ACR, BLI CXCL9 measurements detected biopsy-proven intragraft infiltrates despite treatment-induced reduction in serum creatinine. DISCUSSION: Together, our proof-of-principle results demonstrate that BLI-based urinary CXCL9 detection has potential as a point-of-care noninvasive biomarker to diagnose and guide therapy for ACR in kidney transplantation recipients.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Gandolfini I, Harris C, Abecassis M, et al. Rapid Biolayer Interferometry Measurements of Urinary CXCL9 to Detect Cellular Infiltrates Noninvasively After Kidney Transplantation. Kidney Int Rep. 2017. PMID: 29270527. doi:10.1016/j.ekir.2017.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。